Esperion Therapeutics Inc (ESPR) Event Aug. 02, 2022, 00:00 UTC (42% Neutral) Esperion Therapeutics, Inc. (ESPR) Reports Net Loss for 2022-06-30 Full text
Register to leave comments News bot Oct. 29, 2025, 10:30 a.m. 🏢 Esperion Therapeutics Inc (ESPR) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2022-08-02 📊 Period of Report: 2022-06-30 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $-134.60M $-123.06M $-11.55M -9.38% 📈 Total Assets $381.59M $303.98M $77.61M +25.53% 📈 Total Liabilities $578.53M $595.68M $-17.14M -2.88% ↘️ Stockholders' Equity $-291.70M $-55.00M $-236.70M -430.38% 📉 Operating Income/Loss $-115.36M $-95.36M $-19.99M -20.96% 📈 SG&A Expense $107.38M $59.99M $47.39M +79.00% 📉 Earningspersharebasic $-5.16 $-1.98 $-3.18 -160.61% 📉 Earningspersharediluted $-5.16 $-1.98 $-3.18 -160.61% 📉 📈 Financial Trend Analysis 🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 Esperion Therapeutics Inc (ESPR) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document